If anyone read my last post, I spoke briefly about PRRTs and more specifically, 177Lu-dotatate, which was approved by the FDA in 2018. "The ORR was 16% (n=58), including 3 complete responses in this subset of
360 patients with GEP-NETs who were assessed according to RECIST
177Lu-dotatate hardly even works and here's a presentation in which Dr Price (who's running our NETs trial) talking about way to prevent Carcinoid crisis in patients using PRRTs when being treated for positive metastatic and/or inoperable neuroendocrine tumours.
Carcinoid crisis can be fatal and people with Carcinoid Syndrome have very uncomfortable symptoms diarrhea and nausea. If you had a chance to read the article about the PV-10 trial that I'll link again in this post, you'll notice that the patient that took part in the PV-10 trial was able to attend his daughters wedding because these same symptoms were diminished for him to the point that he was able to reclaim his life back.
These same exact symptoms can be INCREASED to higher levels and to levels so high that the patients even die with the current FDA approved drug 177Lu-dotatate! What's worse is that it hardly even works on the tumors it's meant to treat! Some of these patients could be going from bad to worse with very little hope that they'll even benefit from the treatment.
I bet you that PV-10 doesn't have this problem...